[Current status and future prospects in HMGB1 and receptor researches].
High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.